



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

~~In re application of~~

: Confirmation No. 7196

Tetsunori FUJISAWA et al.

: Docket No. 2000\_0562A

Serial No. 09/581,402

: Group Art Unit 1634

Filed June 12, 2000

Examiner Jeffrey N. Friedman

## NOVEL METALLOPROTEINASE INHIBITORS

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
IN FORMIA 22-0076

**PATENT OFFICE FEE TRANSMITTAL FORM** 0,23-0975.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Siri

Attached hereto is a check in the amount of **\$2,010.00** to cover Patent Office fees relating to filing the following attached papers:

**Petition for Extension of Time (5 month) .....** \$2,010.00

Other: .....

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Tetsunori FUJISAWA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
June 8, 2004

[Check No. 62192 ]  
2000\_0562A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 7196**  
Tetsunori FUJISAWA et al. : Docket No. 2000\_0562A  
Serial No. 09/581,402 : Group Art Unit 1634  
Filed June 12, 2000 : Examiner Jeffrey N. Fredman

NOVEL METALLOPROTEINASE INHIBITORS

---

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

**RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is responsive to the Official Action dated December 8, 2003, the time for responding thereto being extended for five months in accordance with a petition for extension submitted concurrently herewith.

The Official Action constitutes a requirement for restriction.

Applicants elect to prosecute the invention of "Groups 1-34, claims 23-25, drawn to enzyme inhibitor compounds".

This response is made with traverse.

The restriction requirement is unduly burdensome and does not comply with PTO practice. The claimed compounds have a common core and common activity.

Moreover, restriction is improper because the present claims were added in Applicants' last response as a result of the direct invitation of the Examiner to do so. See the paragraph bridging pages 2-3 of the Action dated April 14, 2003.

Favorable reconsideration and withdrawal of the restriction requirement is solicited.

Respectfully submitted,

Tetsunori FUJISAWA et al.

By: Warren Cheek  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 8, 2004